相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer
James W. Welsh et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Analysis of Treatment Outcomes of Intraventricular Chemotherapy in 105 Patients for Leptomeningeal Carcinomatosis from Non-Small-Cell Lung Cancer
Ho-Shin Gwak et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer
Eunyoung Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases-One with a remarkable thoracic response as well
J. L. Kuiper et al.
LUNG CANCER (2013)
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
Yosuke Togashi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Metastatic to the Brain
Mariam Jamal-Hanjani et al.
CLINICAL CANCER RESEARCH (2012)
Leptomeningeal Metastasis from Non-small Cell Lung Cancer Survival and the Impact of Whole Brain Radiotherapy
Patrick G. Morris et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
High-dose Erlotinib for Refractory Brain Metastases in a Patient with Relapsed Non-small Cell Lung Cancer
Akito Hata et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
Roy S. Herbst et al.
LANCET (2011)
Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
Christian Grommes et al.
NEURO-ONCOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
Stephanie Heon et al.
CLINICAL CANCER RESEARCH (2010)
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
Jennifer L. Clarke et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
Hajime Asahina et al.
ONCOLOGY (2010)
Carcinomatous Meningitis in Non-Small-Cell Lung Cancer: Response to High-Dose Erlotinib
Nirav Dhruva et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib
Tatsuya Katayama et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI
Hyeon Gyu Yi et al.
LUNG CANCER (2009)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib
David M. Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A Phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer
Daniel I. Milton et al.
CANCER (2006)
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp
Y Nagai et al.
CANCER RESEARCH (2005)
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
AMP Omuro et al.
CANCER (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Current management of brain metastases, with a focus on systemic options
CJ Langer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
